drugset / Trial / NCT02390102

Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement

NCT02390102

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to evaluate the efficacy of Erythropoietin (EPO) (+ iron) in reducing the rate of red blood cell transfusion requirements in patients with aortic stenosis undergoing transcatheter aortic valve replacement.

Timeline

Start
2012-06
Primary completion
2015-06
Completion
2016-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Iron sucrose Unknown 200 mg Intravenous
Comparator epoetin alfa Protein / enzyme biologic 0.75 ug/kg